Capecitabine, DNA/RNA Synthesis Inhibitor

Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.

Nucleoside analogues and nucleobases in cancer treatment - The Lancet Oncology

APExBIO - Capecitabine

Interference with Nucleic Acid Synthesis - Creative Biolabs

Mapping combinatorial drug effects to DNA damage response kinase inhibitors

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Capecitabine, DNA/RNA Synthesis Inhibitor

5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review)

Cancers, Free Full-Text

Gemcitabine (LY 188011), DNA Synthesis Inhibitor

Anti-Cancer Drugs-Medicinal Chemistry

View of Genetic factors affecting patient responses to pancreatic cancer treatment

Frontiers PARP inhibitors combined with radiotherapy: are we ready?

Full article: Facile construction of dual-drug loaded nanoparticles for improvement synergistic chemotherapy in prostate cancer

Metabolic conversion of capecitabine to 5-fluorouracil

5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition - ScienceDirect